Article

Gastric function measurements in drug development

Department of Medicine B, University of Münster, Albert-Schweitzer-Strasse 33, D-48129 Münster, Germany.
British Journal of Clinical Pharmacology (Impact Factor: 3.69). 09/2003; 56(2):156-64. DOI: 10.1046/j.1365-2125.2003.01935.x
Source: PubMed

ABSTRACT The function of the stomach includes initiation of digestion by exocrine secretions such as acid and pepsin, which are under the control of the endocrine secretion of hormones that also coordinate intestinal motility. The stomach also stores and mechanically disrupts ingested food. Various techniques have been developed to assess gastric physiology, the most important of which is assessment of acid secretion, as well as gastric motility and gastric emptying. The influence of drugs on gastric function and the effect of gastric secretion and mechanical actions on the bioavailability of novel compounds are of critical importance in drug development and hence to clinical pharmacologists. The control of acid secretion is essential in the treatment of peptic ulcer disease as well as gastrooesophageal reflux disease (GORD); pH-metry can be used to determine the necessary dose of an acid suppressant to heal mucosal damage. Disturbed gastric myoelectric activity leading to gastroparesis can cause delayed gastric emptying, often found in patients with diabetes mellitus. Electrogastrography (EGG) may be used to evaluate the influence of prokinetics and other drugs on this condition and aid in determining effective therapy.

0 Followers
 · 
94 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite the development of advanced vaccine technology, as many as 15 million deaths occur annually as a result of inadequate prophylactic or therapeutic treatments against infectious diseases (World Health Organization 2008). The emphasis on profitability by the pharmaceutical industry has led to development of high-cost vaccines targeting diseases with high profit margins, resulting in an annual death toll for developing countries that is largely preventable. Daniell and ­co-investigators published the first expression of a vaccine antigen, cholera toxin subunit B, through transgenic tobacco chloroplasts in 2001. The polyploidy nature of the chloroplast genome enables engineering of a high copy number of target gene, while the translational machinery of the plastid directs the synthesis of bioactive proteins with proper folding, disulfide bond formation, and lipidation. Furthermore, gene integration is site-specific, expression is polycistronic, and natural gene containment occurs due to the maternal inheritance of the chloroplast genome. The chloroplast transformation technology (CTT) has been used to express proteins of bacterial, viral, protozoan, and recently mammalian origins that may be subsequently utilized in immunization strategies to produce protective or therapeutic immunity. Such chloroplast-derived vaccines represent an inexpensive and effective means of producing antigen-subunit vaccines. Furthermore, transformation of edible crops such as lettuce could generate stable orally-deliverable vaccine antigens through inexpensive field production and agricultural drying techniques. This platform could therefore obviate cold-chain logistics and the requirement of sterile injectables, drastically reducing downstream production costs of such biopharmaceuticals. With these proof-of-concept studies, focus within CTT is shifting towards establishing a viable platform for human immunization by demonstrating the ­functionality of such chloroplast derived proteins, emphasizing the need to develop edible plant-based alternatives to tobacco, and improving efficacy through ­additional peptide fusion-domains.
    01/1970: pages 69-87;
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study evaluated the utilisation of human pharmacology studies with biomarkers for either efficacy or safety estimation conducted for new drug applications (NDAs) submitted to the Japanese regulatory authority, the Ministry of Health, Labour and Welfare (MHLW). A total of 50 new chemical entities (NCEs) posted on the Websites, which were approved from June 2000 to November 2001, were evaluated by investigating their approval information. The utilisation of human pharmacology studies with biomarkers was evaluated by focusing on the classification referred to biomarkers for either efficacy or safety estimation and timing of studies. The human pharmacology studies with biomarkers for either efficacy or safety estimation were conducted in 20 compounds classified by utilising measures of either efficacy (17 compounds) or safety (seven compounds). In 4 of 17 NCEs, some of the biomarkers in human pharmacology studies were similar to the clinical endpoints for efficacy assessment in therapeutic exploratory and/or therapeutic confirmatory studies. For safety assessment in therapeutic exploratory and/or therapeutic confirmatory studies, clinical endpoints rather than biomarkers in human pharmacology studies were used in all seven NCEs. The timing of each type of clinical study could only be obtained for 15 NCEs. Of these 15 NCEs, human pharmacology studies with biomarkers for either efficacy or safety estimation were conducted on six compounds. There were only two compounds for which human pharmacology studies with biomarkers for efficacy estimation were conducted before pivotal studies such as a therapeutic exploratory study or a bridging study. Our survey suggests that with Japanese NDAs, human pharmacology studies with biomarkers for either efficacy or safety estimation do not play a key role in accelerating drug development and maximising the knowledge gained from confirmatory trials. The relationship between a biomarker and a clinical endpoint should be investigated appropriately for accelerating drug development. We think that the utilisation of human pharmacology studies with biomarkers for either efficacy or safety estimation in the regulatory review process for NDAs should be encouraged with the advancements of drug evaluation research using an appropriate biomarker based on clinical pharmacology.
    Drugs in R & D 02/2005; 6(1):21-34. DOI:10.2165/00126839-200506010-00003 · 1.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In a recent murine study, we showed that impaired gastric digestion supports the induction of fish allergy by protecting the digestion-sensitive major allergen parvalbumin and thus enhancing its sensitizing properties. The aim of the present study was to investigate whether impairment of peptic degradation might also play a role in the effector phase of codfish allergy. The resistance of cod proteins to digestion by simulated gastric fluid was assessed in vitro . Gastric solutions with pH values ranging from 1.25 to 5.0 were prepared, and the influence of the pH on protein degradation was evaluated by means of SDS-PAGE and IgE immunoblotting. The allergenic potency of digested and undigested cod extract was further characterized in RAST inhibition and basophil histamine release experiments. The digestion experiments revealed that codfish proteins were degraded within 1 minute under physiologic gastric conditions. An only marginal pH shift from 2.5 to 2.75 abrogated completely the digestion of cod allergens. In RAST inhibition experiments digested cod extracts showed a reduced IgE-binding capability that was dependent on the digestion time. Moreover, peptic fragments expressed a 10,000 times reduced allergenic potency, as evaluated on the basis of histamine release from human basophils. Codfish allergens have a grossly reduced ability to trigger an intestinal allergic reaction when they are physiologically degraded. Impairment of the physiologic digestion might thus lower the threshold levels of a food allergen in sensitized patients.
    Journal of Allergy and Clinical Immunology 03/2005; 115(2):377-82. DOI:10.1016/j.jaci.2004.10.029 · 11.25 Impact Factor
Show more

Preview

Download
2 Downloads
Available from